Abstract

Disclosed are a cell population of human urine-derived cells positive for CD90, a cell population of myotubes induced from the cell population of the human urine-derived cells positive for CD90, and a method for producing a myotube derived from the human urine-derived cell, comprising a step of separating the human urine-derived cells positive for CD90.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

This composition for treating central nervous system injury comprises a component for increasing the expression of Hnrnpu protein.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A composition for treating central nervous system injury, said composition containing at least one component selected from the group consisting of a component that inhibits the binding between an LDLR and ApoB-100, a component that inhibits the binding between an LDLR and an LDL, a component that inhibits the binding between a pericyte and ApoB-100, and a component that inhibits the binding between a pericyte and an LDL.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Herein, a combination of antisense oligomers or pharmaceutically acceptable salts thereof, or hydrates thereof which cause simultaneous skipping of any two or more numerically consecutive exons selected from the group consisting of the 45th exon to the 55th exon in human dystrophin pre-mRNA is provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention addresses the problem of providing, inter alia, an anti-human CX3CR1 antibody. The present invention relates to, e.g., an antibody against human CX3CR1 having a prescribed CDR sequence, or an antibody fragment of this antibody.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 15/13 - Immunoglobulins
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) below. (1) If the relative abundance of a bacterium of which the nucleotide sequence for 16S ribosomal RNA genes has 97% or higher homology with the nucleotide sequence for 16S ribosomal RNA genes of any one of specified bacteria in a subject is larger in comparison to said relative abundance in a normal person, the subject is determined as being affected by multiple sclerosis or at high risk of being affected by multiple sclerosis; and (2) if the relative abundance of a bacterium of which the nucleotide sequence for 16S ribosomal RNA genes has 97% or higher homology with the nucleotide sequence for 16S ribosomal RNA genes of any one of specified bacteria in a subject is smaller in comparison to said relative abundance in a normal person, the subject is determined as being affected by multiple sclerosis or at high risk of being affected by multiple sclerosis.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 35/74 - Bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The purpose of the prevent invention is to develop and provide a drug for alleviating, resolving, remitting or treating a symptom of a patient who develops aftereffects of a viral infection.　A tricyclic compound represented by general formula (I) and/or general formula (II) or a salt thereof is provided as an agent for preventing aftereffects of a viral infection. [In the formulae, R1represents H or Cl; R2represents H or a methyl group; and R3 represents any one of H, a methyl group, and a functional group represented by formula (III).]

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/14 - Antivirals for RNA viruses

Abstract

It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides a therapeutic agent for progressive disease caused by an increase in Eomes-positive CD4-positive T cells, comprising a compound represented by formula (I) or a salt thereof as an active ingredient. In the formula, R1 is an aldopyranose residue, R2 is a hydrogen atom or a hydroxy group, R3 is —CH2—, —CH(OH)—CH2—, or —CH═CH—, R4 is a hydrogen atom or CH3, x is 0 to 35, and y and z each are an integer satisfying y+z=0 to 3. The present invention provides a therapeutic agent for progressive disease caused by an increase in Eomes-positive CD4-positive T cells, comprising a compound represented by formula (I) or a salt thereof as an active ingredient. In the formula, R1 is an aldopyranose residue, R2 is a hydrogen atom or a hydroxy group, R3 is —CH2—, —CH(OH)—CH2—, or —CH═CH—, R4 is a hydrogen atom or CH3, x is 0 to 35, and y and z each are an integer satisfying y+z=0 to 3.

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides a preventive agent, disease progression inhibitor, or therapeutic agent for central demyelinating diseases, comprising a FFAR1 receptor agonist.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/12 - Genes encoding animal proteins
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61L 27/38 - Animal cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C07K 14/54 - Interleukins [IL]
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Provided are an opioid receptor antagonist, which contains, as an active ingredient, one atropisomer between a pair of atropisomers of a compound represented by formula (1), said atropisomer having an opioid receptor antagonistic action, or a pharmacologically acceptable salt thereof, and a pharmaceutical composition. In formula (1), R1represents a heteroaryl group, etc. and R2and R3 independently represent an alkyl group, etc.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/4965 - Non-condensed pyrazines
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

In the present description, provided is a combination of antisense oligomers, which induce simultaneous skipping of any two or more exons, said exons being consecutive in numerical order, selected from the group consisting of the 45th exon to the 55th exon in the human dystrophin pre-mRNA, pharmaceutically acceptable salts thereof or hydrates of the same.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

In the present description, provided is a combination of antisense oligomers, which induce simultaneous skipping of any two or more exons, said exons being consecutive in numerical order, selected from the group consisting of the 45th exon to the 55th exon in the human dystrophin pre-mRNA, pharmaceutically acceptable salts thereof or hydrates of the same.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

A method for diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is provided in the present disclosure. The present disclosure provides a method that uses the B cell receptor (BCR) repertoire as an indicator of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). One or more variables selected from the group consisting of the frequency of use of one or more genes in the IgGH heavy chain variable region of the BCR in a subject, the BCR diversity index in a subject, and the level of one or more immune cell subpopulations in a subject can be used as an indicator of ME/CFS in the subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention provides a polypeptide having an amino acid sequence capable of binding to NRP1 and an amino acid sequence capable of inducing apoptosis.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61P 37/02 - Immunomodulators
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 15/13 - Immunoglobulins
• C12Q 1/06 - Quantitative determination
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention provides an agent for the treatment or prevention of central demyelinating diseases that contains an APJ receptor agonist.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are: a discrimination method for determining a depressive state in accordance with the age and sex of a test subject; and a system therefor.　In order to determine a depressive state of a test subject, the discrimination method comprises: a measurement step for measuring the pulsation interval of the test subject and the amount of activity associated with the motion of the test subject and represented by an acceleration rate or an angular velocity; a calculation step for calculating the left sides of the following formulas; and a discrimination step for discriminating whether or not the values of the left sides satisfy the magnitude relationship of the respective formulas. [I] Male younger than first predetermined age During waking hours of test subject Formula (1): (LF/HF)/amount of activity>C1 [II] Male at first predetermined age or older During waking hours of test subject Formula (2): (LF/HF)×amount of activityC3 [IV] Female at second predetermined age or older During waking hours of test subject Formula (4): (LF/HF)×amount of activity

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval

Abstract

Provided is an assessment method for determination of being in a depressed state in accordance with the age and sex of a subject. Provided is an assessment method which, in order to determine that a subject is in a depressed state, comprises: a measurement step for measuring pulse intervals of the subject; a calculation step for calculating the left side of an expression below in accordance with the sex and age of the subject; and an assessment step for assessing whether or not the value of the left side satisfies the relation indicated in the expression. [I] Male aged under first predetermined age In waking hours of the subject, (1): (LF/HF) > R1 [II] Male aged first predetermined age or older In waking hours of the subject, (2): (LF/HF) < R2 [III] Female aged under second predetermined age In waking hours of the subject, (3): (LF/HF) > R3 [IV] Female aged second predetermined age or older In waking hours of the subject, (4): (LF/HF) < R4

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A method for preparing myotubes in a non-invasive and simple manner and establishes an in vitro test system of an agent used for exon skipping therapy for muscular dystrophy. The method can prepare myotubes from urine-derived cells by introducing the MYOD 1 gene into urine-derived cells and exposing the urine-derived cells to at least one epigenetic regulatory compound.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/86 - Viral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a therapeutic agent for a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, said therapeutic agent comprising a compound represented by general formula (I) or a salt thereof as an active ingredient. In the formula: R1 represents an aldopyranose residue; R2 represents a hydrogen atom or a hydroxyl group; R3 represents -CH2-, -CH(OH)-CH2- or -CH=CH-; R4 represents a hydrogen atom or CH3; x is 0-35; and y and z are integers satisfying the relationship 0=y+z=3.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention provides a therapeutic agent for a progressive disease caused by an increase in Eomes-positive CD4-positive T cells, said therapeutic agent comprising a compound represented by general formula (I) or a salt thereof as an active ingredient. In the formula: R1represents an aldopyranose residue; R2represents a hydrogen atom or a hydroxyl group; R3222- or -CH=CH-; R433; x is 0-35; and y and z are integers satisfying the relationship 0≤y+z≤3.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders

Abstract

An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/14 - Particulate form, e.g. powders
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided is a drug that allows efficient skipping of the 51st exon in human dystrophin gene. Also provided is an antisense oligomer that has an activity of inducing skipping of the 51st exon in human dystrophin gene.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins

Abstract

Provided is a drug that allows efficient skipping of the 51st exon in human dystrophin gene. Also provided is an antisense oligomer that has an activity of inducing skipping of the 51st exon in human dystrophin gene.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention provides a prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases comprising, as an active ingredient, a substance capable of suppressing or inhibiting production of prolactin.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 25/00 - Drugs for disorders of the nervous system
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present description provides a drug that causes a highly efficient skipping of the 50th exon of the human dystrophin gene. The present description also provides an antisense oligomer that induces skipping of the 50th exon of the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

The present description provides a drug that causes a highly efficient skipping of the 50th exon of the human dystrophin gene. The present description also provides an antisense oligomer that induces skipping of the 50th exon of the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

In the present description, provided are an antisense oligomer that enables simultaneous skipping of a plurality of exons in a target pre-mRNA and a medicinal composition comprising the oligomer. In the present description, also provided is an antisense oligomer enabling simultaneous skipping of two or more exons, said exons being consecutive in numerical order, from a target pre-mRNA, a pharmaceutically acceptable salt thereof or a hydrate of the same, wherein the antisense oligomer contains a base sequence that is complementary to the base sequence of a region containing the vicinity of a donor of any intron in the target pre-mRNA or a region containing the vicinity of an acceptor of any intron in the target pre-mRNA or a partial base sequence thereof.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Abstract

In the present description, provided are an antisense oligomer that enables simultaneous skipping of a plurality of exons in a target pre-mRNA and a medicinal composition comprising the oligomer. In the present description, also provided is an antisense oligomer enabling simultaneous skipping of two or more exons, said exons being consecutive in numerical order, from a target pre-mRNA, a pharmaceutically acceptable salt thereof or a hydrate of the same, wherein the antisense oligomer contains a base sequence that is complementary to the base sequence of a region containing the vicinity of a donor of any intron in the target pre-mRNA or a region containing the vicinity of an acceptor of any intron in the target pre-mRNA or a partial base sequence thereof.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

This swallowing function assessment device is equipped with an impedance acquisition circuit for acquiring the impedance of a muscle of the neck of a subject, and a swallowing function assessment circuit for making an assessment pertaining to the swallowing function of the subject using parameters pertaining to the state of the muscle of the neck of the subject based on the impedance acquired by the impedance acquisition circuit.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body

Abstract

The present invention relates to a method for diagnosing relapsing-remitting multiple sclerosis, the method comprising a step for measuring the relative abundance of bacteria in a stool sample collected from a test subject, and a step for performing the following (1) or (2). (1) If the relative abundance of bacteria having a 16S ribosomal RNA gene nucleotide sequence that is at least 97% identical to any nucleotide sequence indicated by sequence no. 1 or the like, is greater than the relative abundance thereof in a healthy individual, the test subject is determined as being affected by relapsing-remitting multiple sclerosis, or having a high risk of being affected thereby. (2) If the relative abundance of bacteria having a 16S ribosomal RNA gene base sequence that is at least 97% identical to any base sequence indicated by sequence no. 7 or the like, is less than the relative abundance thereof in a healthy individual, the test subject is determined as being affected by relapsing-remitting multiple sclerosis, or having a high risk of being affected thereby.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 35/741 - Probiotics

Abstract

An objective of the present invention is to develop methods capable of determining the severity of neonatal hypoxic-ischemic encephalopathy and predicting prognosis after treatment by therapeutic hypothermia, conveniently and with a high predictive value. The severity of neonatal hypoxic-ischemic encephalopathy can be determined and prognosis after treatment by therapeutic hypothermia can be predicted easily based on whether or not the mass per unit volume of a soluble LOX-1 protein or a fragment thereof contained in blood collected from a subject within 6 hours after birth is equal to or higher than a specific cut-off value.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Provided are: a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus; a method for producing the complex; and a pharmaceutical composition comprising the complex.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 40/00 - Manufacture or treatment of nanostructures
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/02 - Recovery or purification
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

IPC Classes  ?

• A61K 38/20 - Interleukins
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61L 27/38 - Animal cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C07K 14/54 - Interleukins [IL]
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

A reduced attention state estimation system includes an eyeball movement and eyelid activity measurement unit that measures an eyeball movement and an eyelid activity of a subject to obtain eyeball movement and eyelid activity data, a section determination unit that determines an eye opening section, an eye closing section, an eye-blinking section and a cluster section based on the eyeball movement and eyelid activity data, an eyeball movement and eyelid activity-related information calculation unit that calculates a sharpness of microsaccade or the like for each eye opening section based on the eyeball movement and eyelid activity data, and an attention assessment unit that determines an attention assessment or the like for an eye opening/cluster section, which is an eye opening section and cluster section, based on the sharpness of microsaccade or the like.

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints

Abstract

The present invention provides a non-invasive and simple method for producing myotubes, and establishes an in vitro testing system for an exon-skipping therapeutic drug for muscular dystrophy. Specifically, the present invention pertains to a method that is for producing myotubes from cells in urine, and that comprises an introduction step for introducing the MYOD1 gene into cells in urine, and an exposure step for exposing the cells in urine to at least one epigenetic control compound.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• A61P 19/00 - Drugs for skeletal disorders
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

in vitroMYOD1MYOD1 gene into cells in urine, and an exposure step for exposing the cells in urine to at least one epigenetic control compound.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• A61P 19/00 - Drugs for skeletal disorders
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

The present invention pertains to an information processing method which provides information for improving mental state of a user by giving cognitive behavioral therapy over a communication network, the information processing method comprising: acquiring information regarding the attributes and mental state of a user; inputting the acquired information regarding the attributes and mental state into a trained model, which has been trained via machine learning so as to calculate a method of providing information for improving the mental state according to the attributes and mental state of the user, and calculating the method for providing information; and providing the information for improving the mental state of the user to the user over the communication network on the basis of the method calculated by the trained model.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

A method for diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is provided in the present disclosure. The present disclosure provides a method that uses the B cell receptor (BCR) repertoire as an indicator of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). One or more variables selected from the group consisting of the frequency of use of one or more genes in the IgGH heavy chain variable region of the BCR in a subject, the BCR diversity index in a subject, and the level of one or more immune cell subpopulations in a subject can be used as an indicator of ME/CFS in the subject.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12N 15/13 - Immunoglobulins
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided is a motion detection device with which motion detection can be carried out without increasing the computation cost. This motion detection device is equipped with an image acquisition unit for acquiring a subject image, a vector derivation unit for deriving a motion-related vector from the subject image acquired by the image acquisition unit, and a motion detection unit for carrying out motion detection by tracking a vector derived by the vector derivation unit.

IPC Classes  ?

• G06T 7/269 - Analysis of motion using gradient-based methods
• G08G 1/16 - Anti-collision systems

Abstract

The object of the invention is to provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection result being high. The invention also provides a method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any combination thereof in the peripheral blood derived from the subject, and detecting whether or not the subject has mood disorders on the basis of the measurement results.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The objective of the present invention is to develop a method with which it is possible to determine simply and with a high hit ratio the severity of neonatal hypoxic-ischemic encephalopathy and a prognosis prediction after therapeutic hypothermia treatment. The severity of neonatal hypoxic-ischemic encephalopathy and a prognosis prediction after therapeutic hypothermia treatment can be determined easily in accordance with whether or not the mass per unit volume of soluble LOX-1 protein, or a fragment thereof, contained in blood collected from a subject within 6 hours after birth is equal to or greater than a specific cutoff value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The purpose of the present invention is to provide a vector, a promoter and miRNA for the same, and a pharmaceutical composition including the vector, whereby expression of the PLP1 gene can be suppressed specifically in oligodendrocytes in order to treat PMD caused by an abnormality in the PLP1 gene. This oligodendrocyte-specific promoter includes a nucleic acid having at least 90% sequence identity with the base sequence represented by SEQ ID NO: 1. This miRNA specific to the PLP1 gene has a pair of base sequences comprising a predetermined antisense sequence and sense sequence.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/761 - Adenovirus
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/861 - Adenoviral vectors

Abstract

The purpose of the present invention is to provide a vector, a promoter and miRNA for the same, and a pharmaceutical composition including the vector, whereby expression of the PLP1 gene can be suppressed specifically in oligodendrocytes in order to treat PMD caused by an abnormality in the PLP1 gene. This oligodendrocyte-specific promoter includes a nucleic acid having at least 90% sequence identity with the base sequence represented by SEQ ID NO: 1. This miRNA specific to the PLP1 gene has a pair of base sequences comprising a predetermined antisense sequence and sense sequence.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/761 - Adenovirus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/861 - Adenoviral vectors

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

Provided are a method for generating an index for easily and objectively determining neuropsychiatric conditions and a device for generating the index. This generation method for an index for determining neuropsychiatric conditions comprises the steps of: measuring a subject's pulse interval, an activity level represented by the acceleration or angular velocity associated with the subject's movement, and the acceleration TA in the subject's height direction; calculating the backward acceleration NA on the basis of a predetermined condition and calculating a first supine period, a second supine period, a waking period, and a sleeping period; and generating an index represented by a formula including a constant term and a variable term (pulse interval in waking period) × (sleeping period).

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• A61B 5/0456 - Detecting R peaks, e.g. for synchronising diagnostic apparatus
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

It became clear that the therapeutic effect of an IL-6 inhibitor in diseases related to IL-6 and neutrophils can be predicted using the expression level of neutrophil-related genes as an indicator. It also became clear that an IL-6 inhibitor is effective in the treatment of diseases related to IL-6 and neutrophils in patients having a high expression level of neutrophil-related genes. The present invention provides a method for selecting cases of diseases related to IL-6 and neutrophils in which treatment by an IL-6 inhibitor will be effective and carrying out effective treatment of patients having diseases related to IL-6 and neutrophils in whom the expression level of neutrophil-related genes is high.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/09 - Recombinant DNA-technology
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein, and the amino acid substitution occurs at at least one position selected from the group consisting of (1) an alanine residue at position-3, (2) a tyrosine residue at position-6, (3) an alanine residue at position-68, (4) an aspartic acid residue at position-87, (5) a leucine residue at position-91, (6) a serine residue at position-149, (7) a proline residue at position-150 and (8) a serine residue at position-156 in the amino acid sequence for AAV2 VP1 capsid protein or at least one position selected from the positions corresponding to the above-mentioned positions (1) to (8) in an amino acid sequence for a VP1 capsid protein of an AAV other than AAV2; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides a prophylactic agent, an onset-suppressing agent or a therapeutic agent for progressive immune demyelinating diseases, which contains a substance capable of suppressing or inhibiting the production of prolactin as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present invention provides a prophylactic agent, an onset-suppressing agent or a therapeutic agent for progressive immune demyelinating diseases, which contains a substance capable of suppressing or inhibiting the production of prolactin as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A diminished attentiveness state prediction system comprising: an eyeball movement/eyelid activity measurement unit that measures eyeball movement and eyelid activity of a subject, and obtains eyeball movement/eyelid activity data; an interval assessment unit that assesses an open-eye interval, a closed-eye interval, a blink interval, and a repeated occurrence interval on the basis of the eyeball movement/eyelid activity data; an eyeball movement/eyelid activity-related information calculation unit that calculates the microsaccade frequencies, etc., of the open-eye interval on the basis of the eyeball movement/eyelid activity data; and an attentiveness evaluation unit that determines an attentiveness evaluation, etc., for the open-eye interval, and an open-eye/repeated occurrence interval, which is the repeated occurrence interval, based on the microsaccade frequencies, etc.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement

Abstract

The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating or preventing disorders or diseases associated with muscle atrophy, or for promoting muscle regeneration, the composition containing, as an active ingredient, a myogenesis inducing agent composed of miR-199 or an DNA that contains an miR-199 gene encoding the miR-199.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Enterobacteriaceae.

IPC Classes  ?

• C12Q 1/06 - Quantitative determination
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/15 - Medicinal preparations
• C12Q 1/10 - Enterobacteria
• C12Q 1/14 - StreptococcusStaphylococcus
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

[Problem] To provide a method for easily and objectively detecting mood disorders in a subject by measuring the expression levels of prescribed genes in the peripheral blood of the subject, the reliability of the detection results being high. [Solution] A method for detecting mood disorders in a subject, the method having a step for measuring the gene expression levels of ribosomal protein genes, CDKN1C, or any arbitrary combination thereof in the peripheral blood derived from the subject, and detecting whether the subject has mood disorders on the basis of the measurement results.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

An object of the present invention is to provide a pharmaceutical preparation that can promote the proliferation of oligodendrocyte precursor cells to effectively prevent or treat a demyelinating disease. FGF21 acts to promote the proliferation of oligodendrocyte precursor cells, and thus, the administration of FGF21, DNA encoding FGF21, an FGF21 production-promoting substance, and/or FGF21-producing cells is effective for preventing or treating a demyelinating disease.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C07K 14/50 - Fibroblast growth factor [FGF]
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

Provided are a biorhythm determination method and a biorhythm determination device with which the state of a biorhythm can easily be determined. In this biorhythm determination method, a beat interval of a subject is measured at a predetermined measurement time, and at least one of the following conditions [A] to [C] is determined: [A] no recumbent time period exists in an awake time period; [B] the (LF/HF) of a sleep time period is less than the (LF/HF) of an immediately preceding awake time period, and the (LF/HF) of the awake time period is greater than the (LF/HF) of an immediately preceding sleep time period; and [C] the HF of a sleep time period is greater than the HF of an immediately preceding awake time period, and the HF of the awake time period is less than the HF of an immediately preceding sleep time period.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/0456 - Detecting R peaks, e.g. for synchronising diagnostic apparatus

Abstract

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a neurodegenerative disease on the basis of the effect of the aforesaid drug. Provided is a therapeutic agent for a neurodegenerative disease which comprises an agent for enhancing synapse formation, said agent comprising miR132 or miR212, as an active ingredient.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 35/761 - Adenovirus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/14 - Particulate form, e.g. powders
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: The present invention provides a GM-CSF-producing T-cell control agent comprising a glycolipid compound represented by the following formula (I) or a salt thereof as an active ingredient: wherein R1 represents an aldopyranose residue, R2 represents a hydrogen atom or a hydroxy group, R3 represents —CH2—, —CH(OH)—CH2—, or —CH═CH—, R4 represents a hydrogen atom or CH3, x is 0 to 35, and y and z each represent an integer that satisfies y+z=0 to 3.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides

Abstract

The present invention provides a clinically useful and objective biomarker with which it is possible to evaluate the severity of depression. The present invention is a biomarker for evaluating the severity of depression, wherein the biomarker comprises at least one selected from the group consisting of 4-aminobutyric acid (γ(gamma)-aminobutyric acid: GABA), arginine, argininosuccinic acid, isoleucine, indolecarboxaldehyde, potassium indoleacetate, carnitine, acetyl carnitine, ornithine, xanthurenic acid, kynurenic acid, kynurenine, citric acid, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyric acid, phenylalanine, proline, betaine, and lysine.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides an oligomer that enables skipping of exon 45 in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

The present invention provides an oligomer that enables skipping of exon 45 in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention pertains to an autoimmune disease diagnosis method comprising a step for measuring a relative existing amount of bacteria included in a fecal sample collected from a test subject, and a step for performing the following (1) or (2): (1) when a relative existing amount of a bacteria, of which the base sequence of 16S-ribosomal RNA gene has an identity not lower than 99% with respect to the base sequence specified by SEQ ID NO: 3 or 4, is larger than the relative existing amount in a healthy individual, determining that the test subject is affected with, or has a high risk of being affected with an autoimmune disease; or (2) when a relative existing amount of a bacteria, of which the base sequence of 16S-ribosomal RNA gene has an identity not lower than 99% with respect to any one of the base sequences specified by SEQ ID NO: 5-23, is smaller than the relative existing amount in a healthy individual, determining that the test subject is affected with, or has a high risk of being affected with, an autoimmune disease.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 35/74 - Bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 37/02 - Immunomodulators
• C12Q 1/06 - Quantitative determination
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided is a novel mental illness therapeutic agent. A mental illness therapeutic agent having an IL-6 inhibitor as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

It is found that the therapeutic efficacy of an IL-6 inhibitor on an MS patient can be predicted by employing, as a measure, the amount of plasmablasts and/or an index of a change of immature plasmablasts (e.g., the amount of immature plasmablasts, the amount of follicular helper T cells) in an MS patient in which plasmablasts exist in a large quantity. It is also found that an IL-6 inhibitor can induce high-level expression of plasmablasts and is effective on MS in which the index of a change of immature plasmablasts is high. According to the present invention, a clinical condition of MS on which a treatment with an IL-6 inhibitor is effective can be selected, and a therapeutic method effective on an MS patient in which plasmablasts can be expressed at a high level and the index of a change of immature plasmablasts is high is provided.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.

IPC Classes  ?

• C12Q 1/06 - Quantitative determination
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The morphinan derivatives represented by general formula (I) (wherein R1 represents hydrogen, a C1-10alkyl, a cycloalkylalkyl in which the cycloalkyl moiety has 3-6 carbon atoms and the alkylene moiety has 1-5 carbon atoms, or the like; R2 represents a heterocycle including at least one carbon atom and 1-4 heteroatoms selected from among N, O and S as constituent annular atoms, with at least one set of adjacent constituent annular atoms having a double bond, said heterocycle also including at least one oxo group as a substituent; Y is bonded to a carbon atom that is a constituent annular atom of R2; R3, R4 and R5 represent hydrogen, hydroxy or the like; R6a and R6b represent hydrogen or the like; R7 and R8 represent hydrogen or the like; R9 and R10 are the same or different, and represent hydrogen or the like; X represents O or CH2; and Y represents C(=O)), variants and stereoisomers of the derivatives, pharmaceutically acceptable salts thereof, and solvates thereof according to the present invention are used as antianxiety drugs, antidepressants and the like.

IPC Classes  ?

• C07D 471/08 - Bridged systems
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are a method and a kit for easily and accurately determining whether or not a test sample contains a cannabinoid. It was confirmed that a synthetic cannabinoid harmful to human body can be easily and accurately detected without using vital cells or special devices by adding, to a plate on which a cannabinoid receptor is solid-phased, a labeled compound having a high affinity to the cannabinoid receptor and the synthetic cannabinoid extracted with a surfactant or an organic solvent and competitively reacting the same.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent

Abstract

Developed and provided is a marker for determining mental illness with which it is possible to easily and accurately determine the presence of schizophrenia, depression, or bipolar disorder in a subject. Provided is a marker for determining mental illness from groups comprising miRNA that contains a base sequence shown by SEQ ID NOS: 1-193, the miRNA being contained in cerebrospinal fluid.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing